How drug prices and payment reform are changing the pharmacy benefit business

How drug prices and payment reform are changing the pharmacy benefit business

By Bob Herman  |  September 26, 2015

The pharmacy benefit management industry has been quietly changing amid healthcare payment reforms and an increasingly fierce debate over drug prices. Now a leadership shuffle at Express Scripts has experts speculating that the days of PBMs as stand-alone companies may be numbered.

Gilead beats Q2 forecasts

By Associated Press  |  July 28, 2015

Gilead Sciences on Tuesday reported second-quarter earnings of $4.49 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.92. Earnings, adjusted for costs related to mergers and acquisitions and stock option expense, came to $3.15 per share.

Pricey successor overtakes $1,000-per-pill Sovaldi

By Associated Press  |  July 13, 2015

Sovaldi, the $1,000 pill for hepatitis C, is no longer the favorite of patients and doctors. The new leading pill is more expensive, and the number of patients seeking a cure has surged.

FDA decisions expected on pricey new cholesterol drugs

By Steven Ross Johnson  |  July 04, 2015

The Food and Drug Administration may issue approval decisions this month and next for two cholesterol-lowering drugs that could drive the nation's drug costs even higher.

Two new cholesterol drugs raise questions of cost and access

By Steven Ross Johnson  |  June 10, 2015

FDA advisory panels this week recommended approval of two drugs that may significantly lower cholesterol. But experts warn the potential high cost for these blockbuster drugs could limit their access and once again raise concerns about skyrocketing prescription costs.

Novartis still biggest drugmaker; Gilead sees huge growth

By Michael Sandler  |  May 23, 2015

A strong sales year for its prescription products and participation in emerging markets enabled Novartis Corp. to maintain its position as the largest pharmaceutical company in 2014. Meanwhile, Actavis saw a 50.5% revenue increase, and Biogen's revenue grew by 40%.

Hepatitis C drug sales boost AbbVie

Hepatitis C drug sales boost AbbVie

By Bob Herman  |  April 23, 2015

Sales of Viekira Pak, the hepatitis C treatment manufactured by pharmaceutical giant AbbVie, totaled $231 million in the first quarter of this year—instantly making it the company's third best-selling drug.

AbbVie report to update hepatitis C drug war

By Bob Herman  |  April 18, 2015

Pharmaceutical company AbbVie will unveil its first-quarter earnings Thursday, giving investors and industry observers their first glimpse of what a full quarter of sales looks like for its new hepatitis C treatment.

Specialty drugs, Medicaid expansion drive jump in prescription spending

By Steven Ross Johnson  |  April 14, 2015

Spending in the U.S. on prescription drugs rose by 13% in 2014, driven largely by increased spending on new breakthrough medications, according to a new report. And Medicaid patients' spending on drugs rose much faster in states that expanded Medicaid under the ACA compared with those that did not.

When it comes to pricing Sovaldi, how NICE of them

By Merrill Goozner  |  March 17, 2015

New cost-effectiveness analyses of Sovaldi and other treatments to treat chronic hepatitis C infection suggest U.S. firms initially set prices near the ceiling that the United Kingdom's National Health Service will pay for drugs.

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.